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Abstract
Background: Changes in lipid levels over time after acquiring HCV infection, and how they differ from HCV-uninfected
persons are unknown.
Methods: We used ERCHIVES to identify those with a known HCV seroconversion window and persistently negative
controls. We excluded subjects with HIV and hepatitis B and those who received lipid lowering agents. Total Cholesterol
(TC), low-density lipoproteins (LDL), high-density lipoproteins (HDL), triglycerides (TG) and non-HDL cholesterol were
retrieved at yearly intervals and plotted over time.
Results: Among 1,270 HCV+ and 5,070 HCV- subjects, median age [IQR] was 47[37,53] for HCV+ and 52[47,57] for the
HCV- group; 69 % were White and 91 % were males in each group. Mean BMI [SD] was 26.94[6.73] in the HCV+ and 28.15
[5.98] in the HCV- group (P < 0.001). Over a 10-year follow-up period among HCV+ persons, TC decreased by (mean (SD)
mg/dL) 12.06(36.95), LDL by 9.22(31.44), TG by 13.58(87.01) and non-HDL-C by 12.55(35.14). Among HCV- persons, TC
cholesterol decreased by 4.15(31.21), LDL by 4.16(26.51); TG by 4.42(82.34) and non-HDL-C by 5.78(30.17).
Conclusions: After HCV acquisition, TC, LDL, TG and non-HDL-C progressively decline over time independent of BMI and
liver fibrosis. Consequences of lipid changes and the need and optimal timing of lipid lowering therapy in HCV+ persons
require further study.
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Background
Hepatitis C virus (HCV) infection has been associated
with alterations in lipid levels. Persons with HCV infec-
tion have significantly lower total cholesterol (TC), low
density lipoprotein (LDL) and triglyceride (TG) levels
compared with demographically similar HCV uninfected
controls. In a previous study of 82,083 HCV infected
and 89,582 HCV uninfected controls, TC was 32 mg/dL
lower, LDL was 18 mg/dL lower and TG were 25 mg/dL
lower among HCV infected persons. [1] Other studies
have shown similar associations.[2–4] Some previous re-
ports offer a cross-sectional comparison at baseline for
those particular studies and do not account for duration
of HCV infection or changes in lipid profile over time.
Others have reported on changes in lipid profiles after
treatment for HCV.[5–8] To our knowledge, no studies
have reported the changes in lipid profile after HCV ac-
quisition and how they compare with demographically
similar HCV uninfected persons.
It is currently unknown whether the changes in lipid
profile among HCV infected persons are present even at
time of HCV acquisition thus reflecting differences in
demographic, behavioral and anthropometric parameters
before infection or whether HCV infection itself triggers
changes in the lipid profile. Temporal changes in lipid
profile over time after HCV acquisition are also unknown.
We used a previously described cohort with a known sero-
conversion timeframe within the Electronically Retrieved
Cohort of HCV Infected Veterans (ERCHIVES) [9] to
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determine the changes in lipid profile over time among




Construction of ERCHIVES has been described in sev-
eral previous publications.[1, 10–18] Briefly, ERCHIVES
contains all HCV infected persons identified via a posi-
tive HCV antibody test within the Veterans Affairs
Healthcare System (VA) nationally between 2002–2013.
Controls are age (5-year blocks), race and gender
matched (1:1) with a negative HCV antibody test in the
same year as the positive test for HCV infected group.
Demographic, clinical, laboratory, pharmacy and mortal-
ity data are extracted from various national VA reposi-
tories and merged using scrambled social security
numbers accordingly to a well-established algorithm.
For the current study, we identified persons within
ERCHIVES with a first negative HCV antibody test
followed by a positive HCV antibody test and no subse-
quent negative HCV antibody test. We excluded persons
with HIV infection and a positive hepatitis B surface
antigen (HBsAg). We also excluded persons with no
lipid profile measurement at baseline and no measure-
ment > 24 months after baseline. We further excluded
persons with missing or undetectable HCV RNA and
baseline and those who were prescribed any lipid lower-
ing agents for >28 days. Persons who received HCV
treatment were censored at the time of treatment initi-
ation. For each person finally identified, we identified up
to four controls, matched on age (5-year blocks), race
and gender, who had at least one negative HCV antibody
test within 12 months of the first positive HCV antibody
test among the seroconversion group. Controls were fur-
ther required to have at least one more negative HCV
antibody test to account for the testing bias for the sero-
conversion group, and no positive HCV antibody test
ever after. Those with HIV infection, positive hepatitis B
surface antigen, missing lipid profiles and who received
lipid lowering agents were excluded similar to the sero-
conversion group.
Measurements
Lipid profiles were obtained during the course of routine
clinical care. Since these values were obtained from elec-
tronic medical records, the proportion of persons who
were fasting at time of testing is not known. Baseline
value was taken to be the average of two most recent
values prior to baseline. Lipid profiles were subsequently
retrieved on yearly basis, using the values closest to the
yearly time points. Non-HDL cholesterol (non-HDL-C)
was calculated by subtracting HDL cholesterol from TC.
Comorbidities were defined using lab values and/or
disease codes using International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9 CM) as
previously described.[1, 9] Use of lipid lowering agents
was defined as prescription of any drug approved for the
treatment of elevated lipid levels for >28 days. Body mass
index (BMI) was calculated as weight divided by the
square of height (kg/m2) and categorized into underweight
(BMI < 18.5), normal weight (BMI 18.5–24.9), overweight
(BMI 25.0–29.9) and obese (BMI ≥ 30.0). Degree of liver
fibrosis was measured by using FIB-4 score, calculated as
follows:
FIB‐4 ¼ age years½ 
 AST IU=L½ =platelet count platelets  109=L 
 ALT1=2 IU=L½ 
 
Analysis
Baseline demographic and clinical characteristics and
lipid profile were compared between HCV infected and
uninfected persons using chi-square for dichotomous
and t-test for continuous variables. We plotted changes
in each of the lipid fractions, TC, LDL, HDL, TG and
non-HDL-C, over time for HCV infected and uninfected
persons. To understand the changes in lipid profile, we
also tabulated and plotted each lipid fraction over time
by BMI category (at baseline) and HCV genotype.
We performed additional analysis when plotting by
HCV status, adjusting for severity of liver fibrosis
using time-updated FIB-4 scores. A p-value of <0.05
was considered significant where comparisons were
made. We used SAS® (SAS Institute Inc., Cary, NC) and
Stata® version 11 (Stata Corp, College Station, TX) for
statistical analyses.
Regulatory approvals
The study was approved by the Institutional Review Board
at VA Pittsburgh Healthcare System. Appropriate approvals




Within ERCHIVES we identified a total of 10,769 persons
with a known window for HCV seroconversion (Fig. 1).
After excluding those with HIV infection (N = 594), posi-
tive hepatitis B surface antigen (N = 894), missing lipid
profiles or HCV RNA at baseline (N = 4,432) and those
with undetectable HCV RNA at baseline (N = 1,873), there
were 1,270 persons available for analysis. We identified
5,070 HCV uninfected controls matched on the criteria
described above. Median age [IQR] was 47 [37,53] for
HCV+ and 52 [47,57] for the HCV- group. There were
69 % White, 20 % Black and 3 % Hispanics and 91 % were
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male in each group. (Table 1) Mean BMI [SD] was 26.94
[6.73] in the HCV+ and 28.15 [5.98] in the HCV- group
(P < 0.001). The prevalence of hypertension was lower
while alcohol and drug abuse and dependence diagnoses
were higher among HCV+, compared with HCV- persons.
Prevalence of stage 3–5 chronic kidney disease and
cardiovascular disease was similar in both groups.
There were small but statistically significant differ-
ences in all lipid fractions between HCV+ and HCV-
groups. (Table 1) Total cholesterol, LDL and non-HDL-
C were lower while TG and HDL was higher among
HCV infected compared with HCV uninfected persons.
Changes in lipid profile over time
Over the period of follow up, there were significant
changes in most lipid fractions. All non-HDL lipid frac-
tions declined over time for both HCV+ and HCV- per-
sons, with much larger declines observed in HCV+
compared with HCV- persons (Fig. 2). There was no
consistent pattern of change in lipid fractions by BMI
Fig. 1 Study flow sheet
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categories (Fig. 3). Among HCV+ with available geno-
type results, declines in lipid fractions were generally lar-
ger among genotype 3 infected persons, lowest in those
with genotype 2 and intermediate in those with genotype
1 infected persons (Fig. 4). Among HCV+ persons, after
adjusting for time-updated BMI and FIB-4 score, TC
cholesterol decreased by (mean [SD] mg/dL) 12.06
[36.95], LDL decreased by 9.22 [31.44], TG decreased by
13.58[87.01] and non-HDL-C decreased by 12.55
[35.14]. Among HCV- persons, TC cholesterol decreased
Table 1 Baseline characteristics
Variable HCV+ Control* P-value
N = 1270 N = 5070
Age, median (IQR) 47(37,53) 52(47,57) <0.001
Race 0.99
White 69.21 % 69.31 %
Black 20.00 % 19.90 %
Hispanic 3.15 % 3.14 %
Other/not known 7.64 % 7.65 %
Gender (% male) 91.34 % 91.40 % 0.94
Body mass index, mean (kg/m2) 26.94(6.73) 28.15(5.98) <0.001
Underweight (BMI <18.5) 1.02 % 2.37 % 0.003
Normal weight (BMI 18.5–24.9) 37.48 % 29.29 % <0.001
Overweight (BMI 25–29.9) 39.69 % 36.21 % 0.02
Obese (BMI > =30) 21.81 % 32.13 % <0.001
Diabetes 4.41 % 4.73 % 0.62
Hypertension 31.65 % 38.78 % <0.001
Chronic kidney disease 13.78 % 15.50 % 0.13
Cardiovascular disease 3.39 % 4.18 % 0.2
Alcohol abuse or dependence 45.75 % 30.69 % <0.001
Drug abuse or dependence 49.37 % 21.18 % <0.001
ALT, mean (SD) 79.31(114.08) 33.28(22.48) <0.001
AST, mean (SD) 56.36(67.91) 30.18(20.87) <0.001
FIB-4, mean (SD) 1.39(1.7) 1.28(1.05) 0.03
Cirrhosis by FIB-4 > 3.5 (%) 4.86 % 2.95 % <0.001
Total cholesterol, median (IQR) 178.5(154.5,199.5) 180(159,200) 0.02
> = 240 (%) 3.31 % 3.41 % 0.85
LDL, median (IQR) 103.5(83.7,122.5) 106(87.6,124.5) 0.003
> = 190 (%) 0.24 % 0.32 % 0.5
TG, median (IQR) 120(84,173) 110.75(77.5,159) <0.001
> = 500 (%) 0.31 % 0.45 % 0.5
HDL, median (IQR) 45.5(37.4,55) 45.5(38,56.5) 0.04
<40 (%) 32.20 % 30.18 % 0.16






Not available 50.55 %
*Matched samples
TC total cholesterol, LDL low density lipoproteins, HDL high density lipoprotein, TG triglycerides, non-HDL-C non-HDL cholesterol
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by (mean [SD] mg/dL) 4.15[31.21], LDL decreased by
4.16 [26.51], TG decreased by 4.42 [82.34] and non-
HDL-C decreased by 5.78 [30.17] (P-value <0.001 for all
comparisons with HCV+). (Table 2) Since BMI has a sig-
nificant effect on several metabolic parameters, we plot-
ted BMI for HCV+ and HCV- infected groups over time.
(Additional file 1: Figure S1) The BMI in each group
remained relatively stable over time and the difference be-
tween the groups that was observed at baseline appeared
to remain constant. We plotted changed in lipid fractions
over time in HCV+ and HCV- groups adjusted for time-
updated FIB-4 score, and the results were similar to the
unadjusted analysis. (Additional file 2: Figure S2) We also
studied the impact of HCV RNA upon lipid levels. Within
the HCV+ group, we divided subjects into tertiles based
on HCV RNA levels at baseline and plotted lipid
levels over time. (Additional file 3: Figure S3) No major
differences were observed by HCV RNA levels.
Discussion
In this study we observed progressive decline in lipid
fractions other than HDL after HCV seroconversion.
Fig. 2 Changes in lipid levels over time among HCV seroconverted and HCV uninfected persons. a Changes in total cholesterol; b Changes in
LDL-cholesterol; c Changes in HDL-cholesterol; d Changes in triglycerides; e Changes in non-HDL cholesterol
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These declines were significantly more than in a demo-
graphically comparable HCV uninfected group, and
remained significant after adjusting for BMI and degree
of liver fibrosis. Within the HCV seroconverted group,
the changes were generally larger in HCV genotype 3
infected persons, but were not related to the degree of
HCV viremia.
Mounting evidence demonstrates a unique link be-
tween HCV and host lipid dysregulation. Patients in-
fected with HCV have been shown to have significantly
reduced levels of LDL and TC, compared to healthy
matched controls and patients infected with hepatitis B.
[19–22] HCV infection has also been associated with dy-
namic changes in circulating lipid levels. In a recent
retrospective analysis of 38 patients with acute HCV
comparing pre- and post-infection lipid levels, those
with acute HCV showed a significant reduction in TC
and LDL levels compared to baseline. [23] In
addition, the observed hypolipidemia resolved with
HCV viral eradication; those with spontaneous or
treatment-induced viral clearance had a rebound in
LDL and TC to levels at or above their pre-infection
baseline. [23] Such dynamic changes in lipid levels
suggest a direct interaction between the virus itself
and host lipid metabolism. Due to lack of knowledge
of precise time or duration of infection and/or lack of
an appropriate control group, previous studies do not
inform us whether the changes in lipid levels are a
direct consequence of HCV infection, or such
changes are present at time of HCV infection or even
Fig. 3 Changes in lipid levels over time among HCV seroconverted and HCV uninfected persons by BMI categories. a Changes in total
cholesterol; b Changes in LDL-cholesterol; c Changes in HDL-cholesterol; d Changes in triglycerides; e Changes in non-HDL cholesterol
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prior to that. Our study adds significantly to the
current understanding by demonstrating that such
changes occur predominantly after HCV seroconver-
sion, indirect implicating a role of HCV infection in
such changes. The lipid levels (TC, LDL, TG, non-
HDL-C) were only marginally lower among the HCV
infected group at baseline, and declined significantly
more over time for HCV seroconverted persons com-
pared with HCV uninfected controls. Differences in
BMI alone do not fully explain this difference, since
BMI remained relatively constant over time for both
HCV+ and HCV- groups. While the timing suggests
at least a partial role of HCV infection in such declines,
these declines do not appear related to the degree of
HCV viremia.
Fig. 4 Changes in lipid levels among HCV seroconverted persons with available genotype results, by HCV genotype. a Changes in total
cholesterol; b Changes in LDL-cholesterol; c Changes in HDL-cholesterol; d Changes in triglycerides; e Changes in non-HDL cholesterol
Table 2 Changes in lipid levels by HCV status over time,
adjusted for time-updated body mass index, and time-updated
FIB-4 score (change from baseline to last observation)
HCV+ HCV- P-value
TC, mean(SD), mg/dL −12.06(36.95) −4.15(31.21) <0.001
LDL, mean(SD), mg/dL −9.22(31.44) −4.16(26.51) <0.001
HDL, mean(SD), mg/dL 0.58(17.04) 1.62(15.78) <0.001
TG, mean(SD), mg/dL −13.58(87.01) −4.42(82.34) <0.001
Non-HDL-C, mean(SD), mg/dL −12.55(35.14) −5.78(30.17) <0.001
TC total cholesterol, LDL low density lipoproteins, HDL high density lipoprotein,
TG triglycerides, non-HDL-C non-HDL cholesterol
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There is biological plausibility for our findings. HCV
may alter cholesterol homeostasis through several mech-
anisms. HCV infection may produce hypolipidemia
through its interference with the mevalonate pathway,
resulting in decreased cholesterol synthesis. This di-
minished synthesis may then subsequently upregulate
LDL-receptor expression, ultimately lowering LDL levels.
[19, 23, 24] Hepatitis C viral proteins have been shown to
directly activate the PI3-K/AKT signaling pathway,
resulting in activation of the master regulator sterol
response element binding protein (SREBP), which plays a
critical role in activation of genes essential to fatty acid
and cholesterol biosynthesis. [25–28] Additionally, infec-
tion with HCV is associated with reduced microsomal
triglyceride transfer protein (MTTP), an enzyme critical
for VLDL synthesis, and whose inhibition results in
decreased circulating LDL and cholesterol levels. [29] We
have previously demonstrated progressively increasing
liver fibrosis among both HCV infected and uninfected
Veterans, although the rate of progression and proportion
of persons developing liver cirrhosis is much higher
among HCV infected Veterans. [9] The aging population,
particularly the Veterans in the US, have a high burden of
comorbidities. High burden of comorbid illnesses, e.g.
psychiatric disorders, severs CVD, cancer, etc., are associ-
ated with poor nutritional status, which in turn may lead
to decreases in lipid levels.
The association of metabolic abnormalities and lipid
profiles with various HCV genotypes is unknown. Infec-
tion with HCV genotype 3 is associated with a higher
risk of hepatic steatosis, cirrhosis and hepatocellular car-
cinoma, but its association with insulin resistance has
not been proven. [30–33] We observed a trend towards
lower TC, LDL and non-HDL-C levels in HCV genotype
3 infected persons compared with HCV genotype 1. The
significance of this is unclear and limited by the fact that
genotype results were available for less than half of HCV
infected persons.
Certain limitations of our study need to be considered
when interpreting the results. While the window of sero-
conversion was quite clear, the window was wide and
the precise time of infection could not be determined.
Lipid measurements were done as part of routine
clinical care and the fasting status of subjects was not
known. Some lipid fraction measurements are more
affected by measurement in a non-fasting state than
others. The large number of subjects and multiple
measurements for each subject over time is likely to have
attenuated that effect.
Conclusions
In conclusion, all lipid fractions other than HDL decline
after seroconversion for HCV. Such declines are more
pronounced than in comparable HCV uninfected persons
and persist after adjusting for BMI and degree of liver
fibrosis. Further studies are needed to determine if
these differences in lipid levels translate into risk of
cardiovascular disease and other clinical events, and to
determine the need and optimal time for lipid lowering
therapy in HCV infected persons.
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